Delivery Order SPE2DB22D3401-SPE2DB25FT6AY
- Not listed
- The U.S. Defense Department's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of Ondansetron Orally Disintegrating Tablets 4mg in a quantity of 30 tablets. This is a firm fixed-price delivery order with a ceiling value of $52,217.75 and an ultimate completion date of September 10, 2025. The contract was competitively awarded with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $19,039.16 by the Defense Logistics Agency's Medical Supply Chain on August 19, 2025, for the supply of Ondansetron Orally Disintegrating Tablet 8 mg in quantities of 30 tablets. This firm fixed-price delivery order, which is not set-aside, represents a non-competitive award under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $28,456.56 on August 15, 2025, for the supply of Ondansetron ODT 4 mg tablets in quantities of 30. The contract employs firm fixed pricing and carries an ultimate completion date of August 18, 2025. This delivery order is issued without a set-aside designation, indicating it was competitively awarded. The place of performance is AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania....
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $19,841.99 by the Defense Logistics Agency (DLA) on July 28, 2025, for the supply of Ondansetron HCl 4 mg tablets (500 count). This competitively awarded, firm fixed-price delivery order is expected to be completed by July 29, 2025, with performance occurring at the vendor's Conshohocken facility. The contract carries no set-aside designation,...
- AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, was awarded a competitive delivery order valued at $2,872.80 by the Department of Defense Medical Supply Chain on July 30, 2025, for the supply of Ondansetron ODT 8 mg tablets in quantities of 30 units. The contract is structured as a firm fixed price delivery order with an ultimate completion date of July 31, 2025, and carries no set-aside designation. This award is issued under AmerisourceBergen's broader Indefinite...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of Ondansetron ODT 4 mg tablets in a quantity of 30 units, with a ceiling value of $13,637.20. This is a firm fixed-price, non-set-aside delivery order with an ultimate completion date of July 30, 2025, and represents a child contract under AmerisourceBergen's larger federal contract portfolio. AmerisourceBergen Drug Corp, headquartered in...
- The Defense Logistics Agency awarded a delivery order valued at $6,179.85 to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of Ondansetron ODT 4 mg tablets in quantities of 30. This competitively awarded, non-set-aside contract carries a firm fixed price and is scheduled for completion by August 14, 2025. The award will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its headquarters as a major...
- The Defense Logistics Agency awarded a delivery order valued at $1,962.99 to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 4 mg tablets (30-count packaging) on July 23, 2025, with an ultimate completion date of July 24, 2025. This competitively awarded, firm fixed-price delivery order represents a small-value pharmaceutical procurement with no set-aside designation. The place of performance is listed as Conshohocken, Pennsylvania, which is also the location of AmerisourceBergen...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of Ondansetron ODT 4 mg tablets (30-count units) with a ceiling value of $3,686.07. This competitively awarded, firm fixed-price delivery order represents a continuation of the contractor's critical role in supporting federal pharmaceutical procurement. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order by the Defense Logistics Agency on August 27, 2025, for the supply of Ondansetron ODT 8 mg tablets in quantities of 30 units. This firm fixed-price delivery order, valued at $1,795.50, represents a competitively awarded contract with no set-aside designation and is scheduled for completion by August 28, 2025. The award was executed under AmerisourceBergen's...
- SPE2DB22D3401Indefinite Delivery Contract
- SPE2DB22D3401-SPE2DB25FT6AYDelivery Order
AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, was awarded a delivery order by the Defense Logistics Agency on September 8, 2025, for the supply of Ondansetron ODT 4 mg tablets (30-count) with a contract ceiling value of $6,033.03. This is a firm fixed-price, competitively awarded delivery order with no set-aside designation and an ultimate completion date of September 9, 2025. The performance location is listed as the vendor's corporate office in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (contract SPE2DX), valued at $999,999,999.00 through December 2026. The parent IDC serves as a comprehensive global pharmaceutical support vehicle enabling the company to supply a wide range of medications and medical supplies to support military healthcare programs worldwide, including deliveries to the Defense Health Agency and U.S. Coast Guard. Ondansetron, an anti-nausea medication commonly used in military medical settings, represents one of the specialized pharmaceutical products delivered under this strategic contract vehicle supporting federal healthcare operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $6.0k | 9/8/25 |